Oruka Therapeutics, Inc.
Piper Sandler reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ:ORKA), citing its drug pipeline. The stock is up 290% over 12 months, but currently trades at $79.69. Key catalysts include upcoming data for ORKA-001 and ORKA-002. H.C. Wainwright also reiterated a Buy rating with a $120 target.
Klein Lawrence Otto (Chief Executive Officer) sold 25,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $83.62 ($83.40–$84.78, $2.09M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ORKA (Oruka Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ORKA coverage spans insider activity, technology and financial news.
In the last 30 days, ORKA insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($5.2M). The most active reporter was Agarwal Arjun, Senior Vice President, Finance, with 6 filings. 86% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade and positive trial data could lift the stock.
The insider sale may signal reduced confidence and could weigh on the stock.
Positive trial data may lift ORKA shares as investors reassess the drug's commercial potential.
The data were anticipated and already priced in, leading to a sell‑the‑news move despite strong results.
Strong efficacy and safety signals may boost investor confidence and drive short‑term price appreciation.
AlphAI scores every news story that mentions ORKA with an AI model for sentiment and relevance, and aggregates insider trades from Oruka Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Piper Sandler reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ:ORKA), citing its drug pipeline. The stock is up 290% over 12 months, but currently trades at $79.69. Key catalysts include upcoming data for ORKA-001 and ORKA-002. H.C. Wainwright also reiterated a Buy rating with a $120 target.
2 min readKlein Lawrence Otto (Chief Executive Officer) sold 25,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $83.62 ($83.40–$84.78, $2.09M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readOruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.
2 min readOruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.
2 min readOruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A trial of ORKA-001, showing PASI 100 and PASI 90 rates increased to 71.4% and 87.3%, respectively, without additional dosing. The drug maintained a favorable safety profile. Full 52-week data is expected in December 2026, with 16-week EVERLAST-B data due in 4Q 2026.
2 min readQuinlan Paul T (General Counsel) sold 10,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $93.64 ($92.37–$95.31, $0.94M total) across 4 trades on 2026-09-21 under a Rule 10b5-1 trading plan.
1 min readGoncalves Joana (Chief Medical Officer) sold 7,947 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.38 ($91.10–$95.71, $0.73M total) across 5 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readAgarwal Arjun (Senior Vice President, Finance) sold 10,019 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.43 ($91.11–$95.71, $0.93M total) across 5 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readKlein Lawrence Otto (Chief Executive Officer) sold 2,452 shares of Oruka Therapeutics, Inc. (ORKA) at $95.71 ($0.23M total) on 2026-09-15.
1 min readQuoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.
3 min read